Abstracts tagged "genomics and lupus nephritis"

Abstract Number: 2950 • 2018 ACR/ARHP Annual Meeting
10X Genomics-Based Single-Cell RNA-Seq Analysis Identifies a Transcriptional Landscape of Inflammation and Fibrosis in Lupus Nephritis
Hemant Suryawanshi¹, Evan Der², Pavel Morozov¹, Robert M. Clancy³, Beatrice Goilav⁴, H. Michael Belmont³, Peter M. Izmirly⁵, Nicole Bornkamp⁶, Nicole Jordan⁷, Ming Wu³, Judith A. James⁸, Joel M. Guthridge⁹, Soumya Raychaudhuri¹⁰, Jill P. Buyon³, Chaim Putterman² and Thomas Tuschl¹, ¹Howard Hughes Medical Institute and The Rockefeller University, New York, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³NYU School of Medicine, New York, NY, ⁴Division of Nephrology, Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, ⁵Rheumatology, NYU School of Medicine, New York, NY, ⁶Medicine, NYU School of Medicine, New York, NY, ⁷Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁸Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁰Harvard Medical School, Boston, MA
Background/Purpose: Renal histology remains a primary tool for classification and treatment decisions in lupus nephritis (LN). Single-cell RNA-seq (scRNA-seq) analysis may provide mechanistic insights into…
Abstract Number: L8 • 2014 ACR/ARHP Annual Meeting
Differential DNA Methylation Associated with Lupus Nephritis
Renuka Nayak¹, Sharon A. Chung², Joanne Nitiham³ and Lindsey A. Criswell³, ¹Rheumatology, University of California - San Francisco, San Francisco, CA, ²School of Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ³Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA
Background/Purpose: Genetic and epigenetic factors contribute to the progression of systemic lupus erythematosus (SLE). We now have technologies that allow us to identify these factors…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].